Soleil Boughton Sells 2,334 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 2,334 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $17.30, for a total value of $40,378.20. Following the transaction, the insider now directly owns 164,475 shares in the company, valued at approximately $2,845,417.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, July 23rd, Soleil Boughton sold 2,335 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.29, for a total value of $47,377.15.
• On Tuesday, July 9th, Soleil Boughton sold 2,335 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.28, for a total transaction of $47,353.80.
• On Thursday, May 30th, Soleil Boughton sold 129,667 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.55, for a total transaction of $2,664,656.85.
• On Tuesday, May 28th, Soleil Boughton sold 2,502 shares of Hims & Hers Health stock. The stock was sold at an average price of $17.33, for a total transaction of $43,359.66.
• On Monday, May 20th, Soleil Boughton sold 4,915 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.01, for a total transaction of $98,349.15.
• On Monday, May 13th, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The shares were sold at an average price of $12.33, for a total value of $30,861.99.

Hims & Hers Health Stock Up 0.7 %

Shares of NYSE:HIMS traded up $0.11 during midday trading on Friday, reaching $15.96. 8,244,545 shares of the company traded hands, compared to its average volume of 7,900,966. The firm’s fifty day moving average price is $21.12 and its two-hundred day moving average price is $15.91. The firm has a market capitalization of $3.43 billion, a price-to-earnings ratio of -1,596.00 and a beta of 1.08. Hims & Hers Health, Inc. has a 12 month low of $5.65 and a 12 month high of $25.74.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. The firm had revenue of $315.65 million for the quarter, compared to the consensus estimate of $302.43 million. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. The company’s revenue for the quarter was up 51.8% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.03) earnings per share. Analysts forecast that Hims & Hers Health, Inc. will post 0.2 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on HIMS. TD Cowen upped their price objective on Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a research report on Wednesday. Piper Sandler reissued a “neutral” rating and set a $18.00 target price on shares of Hims & Hers Health in a research report on Tuesday. Finally, Bank of America raised their price target on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock a “buy” rating in a research note on Thursday, June 13th. Eight research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $20.00.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Hims & Hers Health by 1.0% in the first quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock worth $221,379,000 after purchasing an additional 136,907 shares during the last quarter. Forerunner Ventures Management LLC bought a new position in shares of Hims & Hers Health in the 4th quarter worth $86,836,000. Renaissance Technologies LLC raised its position in shares of Hims & Hers Health by 113.1% during the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after buying an additional 3,205,108 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Hims & Hers Health by 9.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,147,927 shares of the company’s stock worth $19,117,000 after acquiring an additional 193,507 shares during the last quarter. Finally, Farallon Capital Management LLC increased its stake in Hims & Hers Health by 3,890.5% in the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after acquiring an additional 1,634,000 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.